Efficacy of radiotherapy for gastric bleeding associated with advanced gastric cancer by 금웅섭 et al.
Lee et al. Radiat Oncol          (2021) 16:161  
https://doi.org/10.1186/s13014-021-01884-5
RESEARCH
Efficacy of radiotherapy for gastric bleeding 
associated with advanced gastric cancer
Joongyo Lee1, Hwa Kyung Byun1, Woong Sub Koom1, Yong Chan Lee2 and Jinsil Seong1* 
Abstract 
Background: Gastric bleeding negatively impacts the quality of life of patients with unresectable advanced gastric 
cancer and is frequently lethal. We investigated the efficacy of RT for palliation of gastric bleeding from gastric cancer 
and identified an optimal radiotherapy (RT) strategy.
Methods: The study analyzed 57 patients submitted to palliative RT for gastric bleeding associated with gastric can-
cer between January 2009 and February 2019. Changes in hemoglobin (Hb) levels were analyzed based on measure-
ments taken before and immediately, 1 month, and 2 months after RT. Re-bleeding after RT was identified as either 
Hb level dropping to < 7.0 g/dL or the administration of a blood transfusion after RT.
Results: The median biologically effective dose (α/β = 10) was 37.5 Gy (range 23.6–58.5). The most common regi-
men was 25 Gy in five fractions. The mean Hb levels before, immediately after, 1 month, and 2 months after RT (6.6, 
9.7, 10.3, and 9.7 g/dL, respectively) were significantly higher than that before RT (all p < 0.001). No significant dif-
ferences in re-bleeding rates were observed according to total dose, fractional dose, and fraction number. Gastric 
tumor response evaluated by computed tomography within 2 months after RT showed partial responses were more 
frequent in patients achieving bleeding control (25.0% vs. 10.8%, p = 0.023) and overall survival was significantly 
improved for bleeding control within 3 months after RT (median, 15.4 vs. 10.0 weeks, p = 0.048).
Conclusions: RT was an effective modality for gastric bleeding control in gastric cancer, which can be achieved with 
a short course scheme with five fractions.
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Background
Gastric cancer accounted for 5.7% of all cancers world-
wide in 2018, with Korea having the highest incidence; 
furthermore, gastric cancer is one of the most common 
causes of cancer-related death [1]. More than 10% of 
gastric cancer patients are associated with bleeding at 
the same time when they were first diagnosed, and more 
than half of them were major bleeding [2]. 5% of upper 
gastrointestinal bleedings are caused by tumor mass, 
with primary gastric cancer the most common cause of 
tumor bleeding [3, 4]. Bleeding caused by gastric cancer 
not only degrades patient quality but can also lead to 
life-threatening conditions due to hematological instabil-
ity. This deterioration of patient condition also interferes 
with cancer treatment; thus, failure to control bleeding 
can lead to a poor prognosis [5].
Treatments for bleeding control include endoscopic 
therapy, transcatheter arterial embolization, and radio-
therapy (RT). Endoscopic therapy showed hemostasis 
rates of 73–100%, making it excellent for bleeding con-
trol; however, the re-bleeding rates were approximately 
40% [5–7]. In particular, predicted endoscopic hemosta-
sis failure was higher for large bleeding lesions (> 2 cm) 
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and non-exposed vessel bleeding [8]. Transcatheter arte-
rial embolization also provides rapid control of massive 
bleeding. However, the re-bleeding rate after the first 
hemostasis is 41–66%, worse than that for endoscopic 
therapy [9, 10]. RT is also effective for tumor bleeding, 
with reported control rates of 50–89% [11–13]. RT is 
non-invasive compared to other treatments; hence, it can 
be used in patients with poor physical condition. How-
ever, the optimal palliative RT strategy has not been well-
established due to a lack of conclusive data.
This study investigated the efficacy of RT for palliation 
of gastric cancer-associated gastric bleeding and sug-
gested an optimal RT strategy.
Methods
Patients
The study analyzed 57 patients who received palliative 
RT for gastric cancer-associated gastric bleeding between 
January 2009 and February 2019 at Yonsei Cancer Center. 
In all patients, gastric bleeding was confirmed by esoph-
agogastroduodenoscopy. Patients who neither had RT/
gastric bleeding-related records or complete RT were 
excluded. We evaluated 57 patients who were eligible for 
our study.
This study was approved by the Severance Hospital 
institutional review board(No. 4-2020-1305), and the 
requirement for informed consent was waived because of 
the retrospective nature of this study. All methods were 
carried out in accordance with relevant guidelines and 
regulations.
Radiotherapy
All patients underwent palliative RT using external-
beam RT. The gross tumor volume was defined as the 
gross tumor lesion as seen on computed tomography 
(CT). Internal target volume was defined as considering 
the respiratory movement in the gross tumor volume, 
and four-dimensional CT with free breathing was used 
to account for the respiratory movement. Clinical target 
volume was defined as internal target volume plus 0.3 cm 
margins. Planning target volume was defined as clinical 
target volume plus 0.3 cm margins for set-up uncertainty. 
Dose was prescribed to planning target volume. The bio-
logically effective dose (BED) was calculated to compare 
different RT fractionation regimens. BED was calculated 
according to the following equation: BED = nD[1 + D/
(α/β)], where n = fraction number, D = dose per fraction, 
and α/β = 10 for gastric cancer.
Response evaluation
Re-bleeding after palliative RT was defined as either 
a decrease in the hemoglobin (Hb) level to < 7.0  g/dL 
or blood transfusion after RT with or without an Hb 
level < 7.0 g/dL. The changes in Hb levels were analyzed 
at various time points: the baseline Hb within 1 month 
before initiating RT, Hb at RT completion, at 1 month, 
and 2 months after RT completion.
We also assessed whether our patients no longer had 
clinical symptoms (melena, hematemesis) after RT. These 
clinical symptoms were confirmed through the medical 
record, and it was mainly checked whether the symptoms 
were relieved one month after the end of RT.
In patients who underwent endoscopy after RT, we 
checked whether the bleeding improved on the endo-
scopic findings.
To evaluate the response of gastric tumors by RT, CT 
images were performed within 1 to 2 months after the 
end of RT. Tumor response was determined according to 
Response Evaluation Criteria in Solid Tumors (RECIST), 
version 1.1 [14]. Treatment-related toxicities were graded 
according to the Criteria for Adverse Events, version 5.0 
[15].
Statistical analysis
Cumulative re-bleeding rate (CRR) was defined as the 
time from RT completion to Hb level dropping below 
7.0  g/dL or receiving a blood transfusion after RT with 
or without Hb level < 7.0 g/dL. Overall survival (OS) was 
defined as the time from RT completion to death or last 
patient contact. CRR and OS were analyzed using the 
Kaplan–Meier method and log-rank test. Univariate and 
multivariate analyses for CRR were performed with the 
Cox proportional hazards model.
Repeated-measures analysis of variance (ANOVA) was 
performed to assess the changes in Hb level at each time 
point after RT (the baseline Hb within 1 month before 
initiating RT, Hb at RT completion, at 1 month, and 2 
months after RT completion).
The Pearson χ2 test was used to identify the relation-
ship between the gastric tumor response and bleeding 
control after RT.
P-values lower than 0.05 were considered statistically 
significant. Statistical analysis was performed using IBM 




The baseline characteristics of all patients are listed 
in Table  1. The median age was 61 years (range, 33–87 
years). Fifty-two patients (91.2%) and 5 patients (8.8%) 
were diagnosed with adenocarcinoma and signet ring cell 
carcinoma, respectively. Fifty patients (87.7%) had distant 
metastasis at the time of RT and 7 (12.3%) patients had 
locally advanced disease.
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All but one patient (98.2%) received three-dimensional 
conformal RT (3D-CRT). The remaining one patient 
received intensity modulated RT (IMRT). The median 
total applied dose was  BED10 37.5  Gy (range 23.6–
58.5 Gy). All patients have completed scheduled RT. The 
median dose per fraction was 4.0 Gy (range 1.8–5.0 Gy) 
and a median of 5 fractions (range, 4–25 fractions). The 
most common dose fractionation regimen was 25 Gy in 
five fractions (29.8%), followed by 20  Gy in 5 fractions 
(24.6%) and 30 Gy in 10 fractions (22.8%) (Fig. 1).
Forty-three patients (75.4%) received standard dose 
of chemotherapy before RT, 10patients (17.5%) dur-
ing RT, and 27 patients (47.4%) after RT. Ten patients 
received irinotecan plus folinic acid/fluorouracil, 11 
patients received oxaliplatin plus folinic acid/fluoroura-
cil, 11 patients received capecitabine plus oxaliplatin, 
and 11 patients received S-1 plus cisplatin. There were 46 
patients (80.7%) who underwent endoscopic hemostatic 
treatment before RT.
Changes in symptoms and transfusion
Forty-three patients (75.4%) showed subjective symptom 
improvements one month after the end of RT; melena 
in 27 patients, hematemesis in 10 patients, and both in 
6 patients. The remaining 14 patients (24.6%) continued 
to have subjective symptoms after RT. Among these 14 
patients, eight continued to have melena, two continued 
bleeding as observed through the Levin Tube, and four 
had recurrent hematemesis.
All but one patient received blood transfusions before 
RT, and all of them received transfusions within 1 week 
prior to initiation of RT. There were 50 patients (87.7%) 
who received blood transfusions during RT. After RT, 21 
patients (36.8%) received no further transfusions. The 
median interval from the end of RT to receiving transfu-
sion was 2.9 weeks (range, 0.3–38.9 weeks) in 36 patients 
who received transfusion even after RT.
Table 1 Patient and tumor characteristics
Characteristic N (%)
Age (median years, range) 61 (33–87)
Sex
 Male 35 (61.4)
 Female 22 (38.6)
Performance status (Eastern Cooperative Oncology Group)
 1 26 (45.6)
 2 21 (36.8)
 3 8 (14.0)
 4 2 (3.5)
Histopathology
 Adenocarcinoma 52 (91.2)
 Signet ring cell carcinoma 5 (8.8)
Stage (American Joint Committee on Cancer 8th revision)
 IIA 1 (1.8)
 IIB 2 (3.5)
 IIIA 2 (3.5)
 IIIB 2 (3.5)
 IV 50 (87.7)
Chemotherapy
 Before radiotherapy 43 (75.4)
 During radiotherapy 10 (17.5)
 After radiotherapy 27 (47.4)
Endoscopic hemostasis therapy before radiotherapy
 No 11 (19.3)
 Yes 46 (80.7)
 Baseline hemoglobin (median g/dL, range) 6.6 (3.9–9.9)
Fig. 1 Histogram depicting the distribution of radiation doses for the treatment of gastric bleeding
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Endoscopic assessment
Twenty-one patients (36.8%) underwent endoscopy 
within 2 months after RT completion. Of these, 14 
(66.7%) were confirmed to stop bleeding completely. Five 
(23.8%) had minor bleeding like oozing, and the other 2 
(9.5%) had no response. No patients were found to have 
new bleeding in another point other than the treated.
Changes in Hb level
The mean of the baseline Hb level within 1 month before 
RT was 6.6 ± 1.3  g/dL, while the mean levels immedi-
ately, 1 month, and 2 months after RT were 9.7 ± 1.0 g/
dL, 10.3 ± 1.1 g/dL, and 9.7 ± 1.6 g/dL, respectively. The 
changes in Hb levels and mean patient Hb levels are 
shown in Fig. 2. Comparison of the mean of the baseline 
Hb level within 1 month before RT to the mean values 
at each time point (immediately, 1 month, and 2 months 
after RT) showed significant increases for all (p < 0.001, 
respectively).
Thirty-five patients (61.4%) had the baseline Hb level 
within 1 month before RT below 7.0  g/dL. All patients 
had Hb levels above 7.0 g/dL immediately and 1 month 
after RT. At 2 months after RT completion, only two 
patients had Hb levels below 7.0 g/dL.
Of the 35 patients with the baseline Hb level within 1 
month before RT below 7.0  g/dL, 14 (38.9%) had levels 
below 7.0 g/dL at least once during the follow-up period 
after RT completion. In contrast, of the 22 patients with 
the baseline Hb level within 1 month before RT above 
7.0 g/dL, 5 (23.8%) had Hb levels below 7.0 g/dL at least 
once during the follow-up period after RT.
Re‑bleeding free rate and toxicity
The median bleeding-free duration after RT was 6.4 
weeks (range 0.3–237.7). CRR at 3 months after RT was 
60.2% (Fig.  3a). CRR was analyzed according to median 
value of several factors in RT but showed no significant 
differences for total  BED10 37.5  Gy (3 months, CRR 
46.4% vs. 69.0%, p = 0.134), fraction dose 4 Gy (3 months, 
CRR 67.7% vs. 54.8%, p = 0.348), or fraction number 5 (3 
months, CRR 52.9% vs. 70.8%, p = 0.303) (Fig. 3). In uni-
variate analysis, younger age (hazard ratio 0.97, 95% con-
fidence interval 0.95–0.99, p = 0.010) and signet ring cell 
carcinoma histology (hazard ratio 4.46, 95% confidence 
interval 1.62–12.26, p = 0.004) were identified poor pre-
dictive factors for CRR. However, multivariate analysis 
showed no independent risk factors associated with CRR 
(Additional file 1).
The gastric tumor response was evaluated in 37 
patients by CT scan within 2 months after RT. Four of the 
37 (10.8%) patients had gastric tumor progression despite 
RT, while 24 (64.9%) had stable disease and nine (24.3%) 
had a partial response. Partial responses were observed 
more frequently in patients with controlled bleeding 
(25.0% vs. 10.8%, p = 0.023) (Table 2).
Among reported treatment-related toxicities, 28 
(49.1%) and 2 (3.5%) patients reported grade 1 and 2 tox-
icity, respectively. No grade 3 or higher toxicities were 
reported.
Survival
Over a median follow-up duration of 13.3 weeks (range 
0.7–237.7), 53 patients died (Fig.  4a). Patients whose 
bleeding was controlled within 3 months after RT com-
pletion showed a significantly improved OS (p = 0.048) 
(Fig. 4b), at 15.4 weeks in 25 patients without re-bleeding 
vs. 10.0 weeks in 32 patients with re-bleeding.
Discussion
The results of this study showed that palliative RT is an 
effective modality for gastric bleeding control in gas-
tric cancer. Although the Hb level before RT was low 
(mean, 6.6  g/dL), the level after RT increased to more 
than 9.7 g/dL. A bleeding-free duration of 6.4 weeks was 
achieved with palliative RT without no grade 3 or 4 toxic-
ities. Tumor response was significantly better in patients 
without re-bleeding and OS was significantly higher in 
patients whose bleeding was controlled within 3 months 
after RT completion.
Previous studies showed that RT is an effective 
modality for gastric bleeding control in gastric cancer. 
Since there is no established dose regimen for palliative 
Fig. 2 Changes in hemoglobin levels in individual patients (thin 
colored line) and mean hemoglobin levels of patients (bold black 
line)
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RT, these studies administered various regimens, with 
fraction doses ranging from 1.8 to 8 Gy and total doses 
from 6 to 60 Gy, corresponding to  BED10 of 7.2–50.8 Gy 
[11–13, 16–19]. Few studies have compared differences 
in treatment outcomes by fraction dose or numbers. 
Sapienza et  al. showed that the fraction number (> 5 
vs. ≤5) was not significantly associated with bleeding 
control [20]. In line with previous reports, our study 
showed no differences in re-bleeding rates according to 
fraction dose and number.
Several studies have assessed the correlation between 
total dose and bleeding controls. One systematic review 
suggested similar bleeding control effects between low 
and high BED regimens [21]. In contrast, several studies 
suggested that higher BED regimens are more effective 
[12, 16, 22], with  BED10 over 36–41 Gy showing signifi-
cantly better local control. In our study, patients were 
administered various regimens, with total dose  BED10 
Fig. 3 Cumulative re-bleeding rates for a all patients and by b total dose, c dose per fraction, and d number of fractions
Table 2 The relationship between bleeding control and tumor 
response





Partial response 5 (25.0) 4 (10.8)
Stable disease 4 (20.0) 20 (54.1)
Progressive disease 0 (0.0) 4 (10.8)
Non-evaluated 11 (55.0) 9 (24.3)
Total 20 37
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of 23.6–58.5 Gy and fraction doses of 1.8–5.0 Gy. While 
short-course schemes were preferred for better compli-
ance, protracted courses were selected for patients with 
large-volume tumors due to concerns regarding toxic-
ity. However, efficacy appeared similar regardless of the 
fractionation scheme, without toxicity. Therefore, short 
fractionation regimens with high fractional doses may 
be reasonable in patients with poor performance status 
or limited life expectancy and those requiring urgent 
symptom control. However, for large tumor volumes, it 
may be better to flexibly administer 30  Gy in 10-frac-
tion regimens.
Due to the difficulty in defining objective parameters, 
no standard has yet been established for evaluation of 
the effect of bleeding control after RT. The most obvious 
method is to check for hemostasis directly through endo-
scopic examinations, but quite a number of patients with 
gastric bleeding have failed to perform post-RT endo-
scopic examinations due to reasons such as poor con-
dition. In our study, 63.2% of patients failed to perform 
endoscopy after RT. Like previous reports, we also used 
clinical symptoms (melena and hematemesis) to evalu-
ate the hemostatic effect of RT [12, 16, 23] and observed 
clinical symptom relief in 75.4% of cases. Other studies 
evaluated the response to RT by reviewing the pre- and 
post-RT Hb levels as well as the reduction in numbers 
of transfused units or volume of transfused blood after 
RT [24, 25]. Hb is an objective measure of bleeding; we 
also showed a significant increase in mean Hb level after 
RT. However, Hb level does not directly reflect acute gas-
tric bleeding and the individual baseline Hb levels var-
ied widely according to underlying comorbidities and 
chemotherapy. Therefore, single Hb measurements may 
be undesirable as a standard evaluation tool for assess-
ing treatment results. In addition, the number of blood 
transfusions does not directly reflect bleeding control 
because of its subjectivity.
Our study proposed two criteria for evaluating re-
bleeding. First, we observed whether the Hb level 
dropped below 7.0  g/dL after RT. This cutoff is consid-
ered a threshold value in restrictive transfusion strategies 
recommended for upper gastrointestinal bleeding [26]. In 
our study, no patients had Hb levels below 7.0 g/dL until 
one month after RT and only two patients received blood 
transfusions because their Hb levels dropped below 
7.0 g/dL at 2 months after RT. Second, we observed if the 
bleeding was confirmed or blood transfusion was admin-
istrated even when Hb levels did not fall below 7.0 g/dL. 
Our criteria aimed to include both Hb level and trans-
fusion in bleeding control evaluation and we defined 
re-bleeding as meeting one of the two criteria, different 
from the definitions used in other studies.
In this study, the Hb level at the immediately end of 
RT was significantly higher than the lowest Hb level 
within 1 month before RT (Fig. 2). This might be related 
to that most of our patients received transfusions 
within 1 week prior to initiation of RT and during RT. 
However, it is noteworthy that the number of patients 
Fig. 4 Overall survival for (a) all patients and (b) by response to radiotherapy
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receiving transfusions after RT has significantly 
decreased. In addition, the Hb level continued to rise 
until a month after the end of RT, which suggests bleed-
ing control through RT. Therefore, RT seems to keep 
the Hb elevation effect of transfusions as long as pos-
sible and to further eliminate additional transfusions.
We also analyzed the association between re-bleed-
ing and OS. The reported duration of response varied 
greatly, with a median ranging from 1.5 to 11.4 months 
[21]. Lee et al. also proposed the use of mean Hb level 
and reduction value in transfusion units within 3 
months after RT [23]. According to our data, patients 
whose bleeding was controlled within 3 months after 
RT completion showed significantly improved OS.
One patient had a baseline Hb concentration of 
12–15  g/dL, which dropped to 9.9  g/dL. Bleeding 
was confirmed by endoscopy. After RT, the Hb level 
increased to 11  g/dL. Although this patient did not 
have significant anemia initially, they received RT due 
to the significant drop in Hb level from baseline. As 
such, RT can be administered flexibly at physicians’ 
discretion even when Hb level criteria are not met. 
Another patient had a drop in Hb level to 4.2  g/dL at 
2 months post-RT, which was the baseline Hb level 
observed in our study. This patient had a diffuse gas-
tric cancer lesion on the entire stomach wall and, thus, 
received RT to the whole stomach, with a dose of 30 Gy 
in 10 fractions. The initial Hb level was 6.9 g/dL, which 
increased to 10.0 g/dL at 1 month post-RT. However, at 
2 months post-RT, the level decreased to 4.2 g/dL, with 
melena re-occurrence. Thus, reirradiation of 20  Gy in 
10 fractions was administered, with no toxicity above 
grade 2. Bleeding control was also successful, with 
melena disappearing and Hb maintained at over 9.0 g/
dL until 1 month post-RT. Thus, reirradiation is also an 
acceptable option when the first palliative attempt fails.
Due to its retrospective nature, this study has some 
limitations. The RT schemes were varied according to 
physician’s preference although some tendency existed 
using a short-course scheme in case large tumor size or 
poor condition of the patients. So there might be selec-
tion bias. Therefore, in the future, it seems necessary 
to plan a prospective study to reduce treatment-related 
errors by specifying a prescription scheme of RT. More-
over, post-RT additional treatment involving chemo-
therapy, which might have affected prognosis, couldn’t 
be fully analyzed. Further study with larger population 
is needed to clarify this issue. Finally, quality survey 
such as European Organization for Research Treatment 
of Cancer (EORTC) QLQ-C30 [27], which could pro-
vide more objective evaluation, was not implemented 
in this study due to retrospective nature. To compen-
sate this, we reviewed each case in detail and checked 
the symptoms at a consistent time point after the end 
of RT.
Conclusions
In conclusion, RT was an effective and well-tolerated 
modality for gastric bleeding control in gastric can-
cer regardless of the fractionation regimen, resulting 
in significantly increased Hb levels. In practical terms, 
the use of a short-course scheme with five fractions is a 
suitable option for patients with poor performance sta-
tus or limited life expectancy, as well as those requiring 
urgent symptom control.
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